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1 Introduction 
1.1 Malaria: 
Malaria is the most devastating parasitic infection Although it has been eradicated from 
several occidental countries, malaria is still present worldwide with the majority of cases in 
the developing world [1]. According to the World Health Organization‟s (WHO) report, 
malaria was endemic in 109 countries in 2008 and in 2006 there were approximately 247 
million of cases and 3.3 billion people at risk. Each year, there are about 1 million of deaths 
and most of them are children under five years old leaving in Sub-Saharan Africa. 
Furthermore malaria cases lead to hundreds millions of days of illness annually in Africa. In 
light of the above the economists conclude that the disease has a huge impact on economy, 
being a definitive cause of poverty in endemic regions [1]. For health and socioeconomic 
reasons there is an urgent need for an anti-malaria treatment, which becomes more and more 
vital because of the spread of resistances that parasites as well as mosquitoes have developed 
against various drugs (like chloroquine) or insecticides (like DTT) which now makes these 
solutions  inefficient in many countries [2]  
1.2 Parasite life cycle 
The Parasite responsible of the disease is Plasmodium which besides Toxoplasma and 
Theileria is part of the Apicomplexa phylum. There are five species of Plasmodium able to 
infect human: P.malariae. P.vivax, P.ovale, P.falciparum and P.knowlesi. Among them 
P.falciparum is causing the most severe and lethal form of malaria [3, 4]. 
P.falciparum is transmitted by the Anopheles mosquito. Infection of the human host starts by 
the bite of a female Anopheles. During the blood meal, motile sporozoites present in the 
salivary glands are directly transferred in the human blood stream. Sporozoites then circulate 
in the blood before they reach the liver where they invade hepatocytes.Each sporozoite 
present in a liver cell divides mitotically into merozoites (which correspond to the first 
asexual stage). After 10 to 12 days, infected hepatocytes burst, releasing several thousand 
merozoites into the blood stream where they invade erythrocytes. In the red blood cells 
merozoites differentiate into immature trophozoites stage called rings. A few hours later rings 
will complete their growth and reach the trophozoites mature stage. Late trophozoites 
subsequently enter in several cycles of nuclear divisions without cytokinesis and reach the so 
called schizont stage because of this schizogonic multiplication. In a single schizont there can 
be up to 32 daughters‟ merozoites which will be finally released directly into the blood stream 
when the rupture of the schizont appears. 
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Figure 1 Plasmodium life cycle [5] 
This intra-erythrocytic cycle of asexual replication is responsible for the disease. The 
alternation of fever and chill observed on patient reflects directly steps of invasion and growth 
in red blood cells [1-3](http://www.icp.ucl.ac.be/~opperd/parasites/malaria4.htm). For reasons 
that are still not completely defined, some parasites differentiate into sexual stages generating 
male and female gametocytes called micro and macro gametocytes, respectively. These 
gametocytes stay in erythrocytes waiting for their uptake by another mosquito during a new 
blood meal. Gametogenesis begins in the stomach of the mosquito and is followed by the 
fusion of the gametes to form a zygote. The zygote maturation leads to a motile ookinete 
which can penetrate the gut epithelium cells and develops into an oocyst. The oocyst then 
enters in many cycles of asexual replication resulting in the generation of several sporozoites 
that, after having reached salivary glands, can be transmittes to another human host during a 
next blod meal. 
http://www.dpd.cdc.gov/DPDx/HTML/malaria.htm 
http://www.tulane.edu/~wiser/malaria/mal_lc.PDF 
1.3 Plasmodium falciparum kinases: 
As mentioned before, the spread of drug resistance in Plasmodium and mosquito makes 
discovery of new compounds an urgent task. To achieve this goal, various approaches are 
used like the development of new vaccines [6], chemical modification of drugs already 
existing and search for innovative molecules [7] as well as genetically modified mosquitoes 
[8]. However, in this work, I will focus only on a recently developed approach based on 
proteins kinases studies. Protein phosphorylation and dephosphorylation, controlled by 
kinases and phosphatases, is one of the major mechanisms of regulation of cellular processes. 
Indeed, changes in the phosphorylation state of a protein can induce changes in their function 
either by increasing or decreasing their activity, by modifying its cellular localisation or by 
changing its interaction with other proteins or by triggering its own destruction [9]. Moreover 
deregulation of this cellular process proved to be involved in various diseases like cancer, 
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neurodegenerative diseases, diabetes and inflammation, which is why development of specific 
kinases inhibitors has been and is still extensively studied to target all the aforementioned 
human diseases [10, 11]. 
Based on the success story of different kinases inhibitors to treat cancers it has become 
interesting to study these molecules in other diseases like Plasmodium falciparum. Thanks to 
bioinformatics, the kinome of P.falciparum has been sequenced and it has revealed some 
homologies between human and P.falciparum proteins but also some divergences which can 
be explained by the phylogenetic distance between malaria parasite and human [12].This 
separation between the host and the parasite makes the use of inhibitors against Plasmodium 
kinases even more interesting since targeting the parasites proteins seems feasible without 
disturbing human proteins [4, 12]. 
 
Figure 2 Phylogenetic distance between eukaryotic organisms 
The human kinome is composed of more than 500 proteins kinases which represent 
approximately 2 % of the genome. Except for a few kinases, the large majority of them shares 
a common amino acid sequence and a similar folding structure and belongs to the eukaryotic 
proteins kinases (ePKs) whereas kinases that don‟t fit within this group belong to the atypical 
proteins kinases family (aPKs). Eukaryotic proteins kinases are divided in seven main 
clusters, namely: 
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1. Casein kinase 1 (CK1). 
2. CMGC for CDK (cyclin-dependent kinases), MAPK (mitogen-activated protein 
kinases), GSK3 (glycogen synthase kinase 3) and CLKs (CDK-like kinases). 
3. TKL (tyrosine-kinase-like) 
4. AGC for PKA (cyclic-adenosine-monophosphate-dependent protein kinase), PKG 
(cyclic-guanosine-monophosphate-dependent protein kinase) and PKC (Protein 
kinase C). 
5. Camk (calcium/calmodulin-dependent kinases). 
6. STE (regulators proteins of MAPKs). 
7. TyrK (tyrosine kinases). 
 
Bioinformatics analysis of the Plasmodium kinome results in the discovery of 86 or 99 ePKs, 
depending on the parameters used, and some other proteins which don‟t fit in ePKs family are 
classified in the other protein kinases group (OPKs) [13]. Distribution of the P.falciparum 
kinases in the main clusters reveals that most of the kinases are found in the CMGC and 
CamK clusters. A few ePKs are in the TKL and AGC clusters, and only one is in the CK1 
group which is quite surprising since this group contains some proteins in other eukaryote 
kinomes. No proteins have been found in the STE and TyrK clusters. Some OPKs belong to 
the NimA (never-in-mitosis A) subgroup and the other proteins do not fit into any group and 
constitute a satellite cluster [12, 13]. 
 
Here we will concentrate on the CMGC family containing containing our proteins of interest 
in this study.. As mentioned above CMGC group is composed of CDKs, MAPKs, GSK3, and 
CLKS. In eukaryotes all these proteins are known to be involved in the control of cell 
proliferation and development. 
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Figure 3 tree-species of CMGC group 
Globally CDKs are regulators of cell-cycle progression; MAPKs are crucial transducers of 
extracellular and intracellular signals. Proteins in the GSK3 family are involved in the 
regulation of cell proliferation and CLKs have functions in RNA metabolism. In P.falciparum 
the kinome it is the most important group in terms of number of proteins which could be 
explained by the number of proliferation stages undergone by the parasite during its life 
cycle[12]. Due to there, expected functions in the cell proliferation of these kinases are being 
extensively studied. Some studies have already shown that different proteins belonging to this 
group are essential for the completion of the parasite life cycle. It is actually the case of my 
proteins of interest P.falciparum CK2β subunits and GSK3 [4].  
I. Introduction 
- 6 - 
1.4 PfCK2: 
Human casein kinase 2 (CK2) is a serine/threonine kinase belonging to the CMGC cluster.  
CK2 is a holoenzyme composed of catalytic subunit α and regulatory subunits β. The 
holoenzyme forms a tetrameric structure composed of two α subunits, respectively CK2α and 
CK2α‟, forming the active site and a dimer of regulatory subunits CK2β that are needed for 
the complex formation [14]. CK2 is present in all the eukaryotic cells in a constitutively 
active manner, despite the fact that the protein is present at a low level, CK2 has a role in 
various cellular processes including neoplasia, differentiation, cell survival, apoptosis and 
proliferation. It also has a suspected role in virus infection as well as in different cancers. The 
kinase has up to 307 substrates. A majority of them has a function in gene expression and 
syntheses of proteins and are transcriptional factors, translational elements or active elements 
of DNA/RNA structure [14-16]. Regulation of CK2 is still poorly understood but probably 
involves interactions with some regulatory proteins [17]. 
P.falciparum casein kinase 2, the CK2 orthologue exhibits some differences at the structural 
level. Homology study reveals that instead of having two catalytic subunits, the P.falciparum 
genome has only one α (PfCK2α) subunit but exhibits two regulatory subunits (PfCK2β1 and 
PfCK2β2). Nevertheless it has been shown that the protein still possesses a kinase activity and 
that the three subunits are able to interact at least in vitro. 
Amino acid sequences analysis reveals that PfCK2α have 65% of its sequence identical to 
CK2‟s sequences including the 11 sub domains conserved in all ePKs and the majority of 
sequences that are conserved in CK2. Alignment between human and Plasmodium β subunit 
also reveals that some features present in CK2β are also present in both PfCK2βs. Sequences 
present in PfCK2β1 and PfCK2β2 are cystein residues required for zinc-finger formation, a 
stretch of amino acids needed for the export of CK2 as a hectokinase, a putative signal for 
nuclear localisation and sequences suspected to be involved in CK2 downregulation and 
association with the plasma membrane. Furthermore both PfCK2β have a lot of sites that can 
be phosphorylated in their C-terminal region. Finally, the N-terminal part of PfCK2β2 
contains a region with phosphorylable sites and on and an extension predicted to be involved 
in interactions with partners and substrates proteins.  
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Figure 4 Alignment of both PfCK2 beta and HsCK2 beta. The cysteine residues thought to hold the zinc in place are 
shown in hold text and with arrowheads. CK2β residues 20 to 33 are responsible for the export of the protein. [18] 
Reverse genetics has been used to analyze functional activity of the PfCK2 subunits. 
Disruption of PfCK2α by single crossover reveals that the „α‟ subunit is needed for the 
completion of the entire asexual life cycle of P.falciparum [18]. The same work has been 
done on both β subunits and leads to the same conclusion (Holland Zoe thesis: Plasmodium 
falciparum Casein Kinase CK2). 
1.5 PfGSK3: 
The protein of interest is glycogen synthase kinase-3 belonging to the same cluster as CK2. 
GSK3 is also a serine/threonine kinase expressed ubiquitously, and constitutively active. This 
enzyme is well known for having a large range of partners in several pathways including 
metabolism, cell cycle, gene expression, development, inflammation and neuroprotection. It is 
also involved in diseases like cancers and diabetes [19, 20]. To exercise all these effects, 
GSK3 interacts with several partners and substrates as, for example, Wnt, Hedgehog, 
cytokines, growth factors and ligands for G proteins [21]. There are two different genes 
coding for two isoforms of the enzyme in human called GSK3α and GSK3β. These enzymes 
have a high level of homology and similar substrates and functions but are not present in a 
redundant manner in all cells [19]. Regulation of GSK3 is mediated by phosphorylation 
(reducing its activity), localisation and interactions with other proteins. These mechanisms of 
regulation imply that GSK3 not only has a lot of substrates but is also a substrate of several 
other proteins [19, 22]. 
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Genome sequencing of the parasite reveals the presence of a homologue of GSK3, the 
P.falciparum glycogen synthase kinase 3(PfGSK3). Bioinformatics analysis demonstrates that 
PfGSK3 also possesses the typical 11 domains shared by all kinases. Furthermore PfGSK3 
has 62.4%/ 58.9% similarities with GSK3α /GSK3β respectively and finally their central 
catalytic domain shares more than 70% amino acids. 
 
Figure 5 Alignment of PfGSK3 with the two human isoforms of GSK3.  [23] 
Several other residues are conserved including the ones that are involved in substrate binding, 
regulation of activity and a region in the N-terminal domain thought to be involved in the 
excretion of the protein. Investigation of the expression of the protein kinase has been done by 
using RT-PCR to analyze the level of expression of its mRNA during the life cycle and shows 
that the protein is expressed throughout all the asexual life cycle but the protein itself is 
mainly expressed during the early trophozoite stage. Furthermore analysis of the intracellular 
localisation of the protein suggests that PfGSK3 colocalises with the Maurer‟s cleft and this 
colocalisation increases during the passage from rings to trophozoites and schizonts. Finally 
the use of inhibitors against PfGSK3 also blocks the proliferation of P.falciparum at least in 
vitro [23]. 
1.6 Reverse genetics study of PfCK2β: 
One part of our project is to complete the work of Zoe Holland on PfCK2β. What we are 
presenting in this discussion is directly taken from her thesis: “Plasmodium falciparum 
Protein Kinase CK2”. We give an overview of her results since most of the materials we have 
used for our project are coming from her work. Their details will be discussed further in the 
chapter on materials and methods.  
Zoe Holland first demonstrated that PfCK2βs locus is recombinogenic. To achieve this goal 
she transfected parasites with a plasmid pCAM-BSD-HA-PfCK2β1 or pCAM-BSD-HA-
PfCK2β2. That plasmid gives the resistance to blasticidin after internalisation and, in case of 
recombination, adds a haemaglutinin tag at the 3‟end of the gene. Parasites were put in culture 
with blasticidin. Zoe then showed that the locus is recombinogenic by demonstrating that 
integration arose, using PCR and Southern blot analysis. 
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Secondly she tried to knockout the PfCK2β genes by transfecting parasites with respectively 
pCAM-BSD-KOPfCK2β1 and pCAM-BSD-KOPfCK2β2. Integration was then monitored by 
PCR and Southern blot analysis. Integration did not appear which in turn showed that these 
genes were essential. Nevertheless to ascertain that the locus can only be disrupted in the 
presence of a complementation plasmid, Zoe did a complementation experiment by co-
transfected parasites with the K.O. plasmid and another plasmid providing with the wild type 
gene as an episome. Experiment was done in duplicate for both PfCK2βs subunits and 
integration arose only for one of each co-transfection. 
1.7 Project introduction: 
CK2 and GSK3 have been extensively studied. We know now that those proteins are involved 
in several pathways and act with various partners and substrates. Interesting studies on PfCK2 
and PfGSK3 have shown that these proteins share homologies with their human counterparts 
including region involved in interaction, phosphorylation and localisation in the cell. Studies 
have also revealed that these proteins are essential for the completion of the parasite life 
cycle. Based on this, we have made the hypothesis that PfCK2 and PfGSK3 are involved in 
various metabolic pathways of P.falciparum. The main part of our project is to use 
biotechnology tools to get an inside in the interactome of PfCK2β subunits and PfGSK3 in 
order to get a better understanding of their functions in the parasites. The aim of the project is 
therefore to use the tagged PfCK2β subunits and PfGSK3 to co-immunoprecipitate  
interactors and use mass spectrometry to identify them. Another part of our project is to 
complete the work of Zoe Holland as discussed above. For this side-project parasites will be 
kept in cultures during few months and integration will be monitored using PCR and Southern 
blot. 
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2. Materials and methods 
2.1 Biological and chemical reagents 
2.1.1 Solutions and buffers 
2.1.1.1. Electrophoresis 
6X DNA loading buffer: 0.25% Bromophenol Blue, 0.25% Xylene Cyanol FF, 30% glycerol 
4X Laemmli buffer: 40% glycerol, 2% SDS, 20% BME, 250 mM Tris-HCl pH 6.9 
1xTAE: Diluted from 10x stock (Invitrogen) in ddH2O to give 40mM Tris-Acetate, 1mM EDTA 
1xTG-SDS: Diluted from 10x stock (BioRad) in ddH2O to give 25mM Tris, 192mM Glycine, 0.1% 
SDS, pH 8.3 
Coomassie stain: 5 g/L Coomassie Brilliant Blue stain (BioRad), 50% ethanol, 10% acetic acid 
Coomassie destain: 45% Methanol, 10% Acetic Acid 
2.1.1.2. Western blotting 
Running gel:  1.83 mL ddH2O , 2.33mL 30
% acrylamide , 2.73mL Tris pH 8.7 1M, 35 µl SDS 20%, 70 µL 
ammonium persulfate 10%, 2.8 µL TEMED (for 2 gels). 
Stacking gel:  1.41 mL ddH2O, 330µL 30
% acrylamide, 250µL Tris pH 6.9 1M, 10 µl SDS 20%, 20µL 
ammonium persulfate 10%, 2 µL TEMED (for 2 gels). 
PBS: 8g/L NaCl, 40mg/L KCl, 1.15g/L Na2HPO4, 328mg/L KH2PO4, 0.1g/L CaCl2, 0.1g/L MgCl2, 
pH7.2, in ddH2O 
Transfer buffer :14.4g/l glycine, 20% methanol and 25mM Tris-HCl pH 8.3 
Wash Buffer (PBS-T): PBS with 0.05-0.3% Tween-20 (Sigma) 
Blocking buffer: PBS tween 0.1% and Blocking grade Milk 5% 
2.1.1.3. Southern blotting 
20xSSC buffer :175,3 g NaCl, 88,2g sodium citrate in 800mL ddH
2
O, adjusted to pH 7 and 
complete to 1000mL 
Depurination solution: 0.25M NaCl 
Denaturation solution: 1.5M NaCl, 0.5M NaOH 
Hybridization buffer :NaCl 0.5 M, 4% blocking reagent Amersham 
Primary wash buffer :60g urea, 25mL SDS20
%
, 50mL sodium phospahate (0,5M final) pH 7.0, 4.35 g 
NaCl, 0.5 mL MgCl2 1M, 1g blocking reagent, complete to 500mL with ddH2O 
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Secondary wash buffer 20x stock: 1M Tris pH base, 2M NaCl adjust to pH 10; dilute 1:20 and add 
2mM MgCl2 
2.1.1.4. Plasmodium culture and protein extract preparation 
Complete RPMI: RPMI 1640 medium completed with 25mM HEPES, 25mM sodium 
bicarbonate, 2mM L-glutamine, 300 mM hypoxanthine, 10 mg/L gentamycin and 5g/L 
albumax II, pH 7.2, filter sterilized and kept at +4°C  
Phenol solution :Phenol:chloroform:isoanylalcohol(25:24:1) in 10mM Tris pH 8 and 1mM 
EDTA 
Saponin solution: 1.5 g L
-1
 saponin in PBS 
Sorbitol solution: 5% sorbitol (w/v) in ddH2O 
Giemsa staining solution: 10% Giemsa, 0.3% Na2HPO4 (w/v), 0.06% KH2PO4 (w/v) in ddH2O 
Freezing solution: 0.583 g L
-1
 sorbitol, 0.125g L
-1
 NaCl, 28% glycerol 
Defrosting solutions: A 12% NaCl (w/v); B 1.6% NaCl (w/v); C 0.2% Dextrose (w/v), 0.9% NaCl 
(w/v) 
RIPA buffer: 30 mM Tris pH8, 150 mM NaCl, 20 mM MgCl2, 1 mM EDTA, 0.5% Triton X-100, 1% 
NP-40, 10 mM -glycerophosphate, 10 mM NaF, 1 mM PMSF, 10 mM Benzamidine, 1x Roche 
Complete protease inhibitors 
2.1.2 Oligonucleotide primers 
The oligonucleotide primers used in this study (custom synthesized by Invitrogen) are listed below. 
Oligonucleotide primers were designed for site-directed mutagenesis, colony screening PCR, and the 
amplification of genes for recombinant protein expression and reverse genetics studies. 
Table 1: Oligonucleotide primers used in this study. Restriction endonuclease recognition sites are underlined. 
CK2b1ForEco GGGGGAATTCATGGAAAATAGTGATTCGAATAAAGAC 
CK2b2RSpe GGGGACTAGTTCATTGACACTCTTCAGAGGATTCCG 
CK2b13primeRev GCATTAAAATATGAGATGTACAC 
CK2b23primeRev CAAACTATGTCAACTGTTTTGGG 
CK2b15primeF CTTAAGTGTTAATCGG 
CK2b25primeF GGCATAGGAATATTTAAC 
pCAMBSDFor TATTCCTAATCATGTAAATCTTAAA 
pCAMBSDRev CAATTAACCCTCACTAAAG 
2.1.3 Antibodies 
Primary and secondary antibodies and their dilutions for western blotting are shown in Tables 2 to 4. 
Antibodies used in this study were bought from commercial suppliers, or commissioned from a 
custom antibody supplier (BioGenes) and were diluted in blocking buffer  
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Table 2 Custom primary antibodies from BioGenes (raised in rabbit) 
Antibody Peptide against which 
antibody was raised 
Antibody stock 
concentration 
Dilution for western 
blotting 
Anti-PfCK2b1 DSNKDLQDSKSDKS-
amide 
0.27 mg/ml  0.38888889 
Anti-PfCK2b2 DEINRDSEEMYKNK-
amide 
0.648 mg/ml 1:750-1:1000 
Anti PfGSK3 CDNEINRSPNKSYKL () 0,98 mg/ml 1/1000 
 
Table 3 Commercial primary antibodies 
Antibody (animal species 
raised in) 
Dilution for western blotting Source 
Anti-HA (mouse) 1:1000 Roche 
 
Table 4 Secondary antibodies 
Antibody (animal species 
raised in) 
Dilution for western blotting Source 
Anti-rabbit IgG (whole 
molecule)-Peroxidase (Goat) 
1:10,000 Sigma 
Anti-chicken IgG (whole 
molecule)-Peroxidase (Sheep) 
1:10,000 Unknown 
2.1.4 Parasites lines 
During this project, eight different parasites lines were cultured. The wild type strain, 3D7A, and 
seven others genetically modified strains from the 3D7A strain. These generated lines were : 
KOCK2b1 and KOCK2b2 :  wild type lines transfected with a plasmid inducing the knockout of the 
genes coding for PfCK2β1 and PfCK2β2. Further more the plasmid used give also a resistance to 
blasticidine  
KOCK2b1 + comp 2 and KOCK2b2 + comp 1 : these lines have been transfected with two plasmids. 
The first was the same as before and the second plasmid provided a wild type copy of the gene. These 
lines have resistance against blasticidin and WR. 
PfCK2β1HA, PfCK2β2HA and PfGSK3HA: these lines have integrated a plasmid adding a 
haemaglutin tag at the 3‟ end of the gene and provide resistance against blasticidin 
Details for the plasmids construction and compositions as well as generation of the lines can be found 
in Zoe Holland thesis : Plasmodium Falciparum casein kinase 2 CK2. 
2.2 Plasmodium Falciparum cell culture techniques 
2.2.1 Malaria parasite culture 
Parasites were grown at a 5% haematocrit in complete RPMI medium and at a parasitaemia (PT : 
number of infected red blood cells / total number of red blood cells) between 0.5% to 10% either in 
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25cm2 (5ml stocks) or 75cm2 (25ml preparative cultures) ventilated flasks. The flasks were kept in a 
37oC incubator with a 5% CO2 atmosphere. The medium was changed daily and the PT was controlled 
every two days by Giemsa-stained blood smears. Fresh blood (erythrocytes concentrate washed and 
kept at 4°C at a concentration of 50% in complete medium) was used to keep the pararasitemia in the 
right range. 
2.2.2 Freezing down cultures 
Cultures were centrifuged for five minutes at 2000g at room temperature and the supernatant was 
removed. One volume of deep-freeze solution was added drop-wise to the pellet. The mix was 
transferred in cryotubes and immediately frozen in liquid nitrogen. 
2.2.3 Defrost parasites cultures 
A frozen cryotube containing parasitized red blood cells was thawed at room temperature and 
transferred into a 15 mL falcon tube. For each mL of blood defrosted, 0.2mL of solution A was added 
drop-wise, stirred constantly and left at room temperature for 3 minutes. Then for each mL of 
original culture volume, 10mL of solution B was added drop-wise and the tube was centrifuged at 
2000 g for 5 minutes. After removal of the supernatant, solution C was added with an equivalent 
volume and in the same way as solution B, the tube was centrifuged at 2000 g for 5 minutes and the 
supernatant discarded. Finally, the pellet was resuspended in complete prewarmed RPMI medium, 
transferred in a small flask and placed in the incubator for daily culture 
2.2.4 Saponin lysis 
Saponin lysis was performed to accumulate parasites pellets. 
Culture was transferred into a 50 ml Falcon tube and centrifuged for 2 minutes at 2000g at 4°C. The 
supernatant was discarded and the pellet washed once with 30 ml of 1X of cold PBS. 10mL of saponin 
(0.15%) was added and solution was resuspended for 10 minutes. When lysis was complete, 45 mL of 
1X of cold PBS was added and the tube was centrifuged at  13000g for 5minutes at 4°C. 
In the case of proteins preparation, an extra saponin lysis was performed with 2mL of saponin. After 
the lysis, the tube was centrifuged as described above and the supernatant removed. 
Then, the pellet was washed 3 times with 10mL of 1X of cold PBS and finally washed an extra time in 
1mL of 1X of cold PBS and transferred into a 1.5ml eppendorf. Once the supernatant was removed, 
the eppendorf was transferred into a -80°C freezer. 
2.2.5 Phenol extraction of DNA 
The volume of parasite pellet was resuspended in 100 µl of PBS.1% of the pellet volume of 
proteinase K  and 11% of the pellet volume of SDS20% were added to the pellet and incubated over 
night at 55°C. DNA was extracted using phenol solution,. 400µl of phenol solution was added in the 
tube. Pelltes with the phenol were vortexed and centrifuged 5 minutes at 16000g. Then, the 
supernatant was transferred to a clean Eppendorf. This step was repeated three times. Finally, 2 
volumes of ethanol 100% and 1% of the volume of sodium acetate 3M pH 5 were added. The tube 
was incubated overnight at -20°C. 
After 15 minutes of centrifugation at 16000g and removal of the supernatant, the pellet was dried 
for 5 minutes at room temperature. Subsequently, DNA was resuspended in 50 µl of ddH2O and DNA 
concentration was measured using a nanodrop. 
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2.2.6 DNA extraction for PCR 
500 µl of cultures with a parasitemia of at least 4% was centrifuged 3 minutes at 2000g and the 
supernatant was removed. The pellet was resuspended in 1ml of ddH20 and left for 15 minutes at 
room temperature. Then, the tube was centrifuged for 3 minutes at 16000g and the supernatant was 
removed. 200µl of pre-agitated InstaGene Matrix (BioRad) was added, the tube was kept 30 minutes 
at 56°C, vortexed and kept 8 minutes at 100°C. Finally, the tube was vortexed, centrifuged, the 
supernatant was transferred into an eppendorf and stored at -20°C. 
2.3. Molecular biology methods 
2.3.1 Polymerase chain reaction 
For DNA amplification we used Phusion polymerase (Finnzyme) for all the analysis. Reactions were 
set up to contain 1X of Phusion HF reaction buffer (supplied with the polymerase), 1.6M of primers 
and 0.2mM of dNTPs. Based on the kit instructions, 0.2 µl of polymerase (2U/µl/250µl), DNA 
(generally 2µl) and ddH2O qsp 25µl were added. The PCR cycle was performed under the following 
conditions: 
Initial denaturation: 94°C, 10 minutes 
35 cycles: 
Denaturation 94°C, 45 seconds 
Annealing 50°C, 45 seconds 
Elongation 68°C, 50 seconds 
Followed by the final elongation 68°C, 10 minutes 
2.3.2 Agarose gel electrophoresis 
Standard agarose gels were prepared in 1X TAE with 1% agarose and 0.5µg/mL ethidium bromide. 
For agarose gel electrophoresis, DNA samples were mixed with 6x loading buffer before loading.. The 
bands were finally visualized either under UV illumination or transillumination linked to a computer. 
2.3.3 Restriction endonuclease digestion 
Restriction endonuclease digestion was used to fragment DNA before southern blot analysis. 10 g of 
DNA was digested in New England Biolabs advised buffer, 1x BSA and 1l of each enzyme in a final 
volume of 30µl completed with ddH2O. The buffer and temperature were chosen based on the neb 
double digestion finder site (www.neb.com/nebecomm/DoubleDigestCalculator.asp). Digestion took 
place at 37°C over-night and tubes were pulse-centrifuged and stored at -20°C. 
2.3.4 Southern blot analysis 
2.3.4.1. Preparation, Migration of digested DNA on Agarose gel: 
Southern blot was used to detect plasmid integration. Parasites DNA was extracted using phenol  
(see section 2.2.5) and DNA concentration and quality was checked using nanodrop and agarose gel 
electrophoresis (see section 2.3.2). Subsequently, DNA was digested (2.3.3) overnight. DNA samples 
were loaded on a 0.8%agarose gel (, and run first at 80V for 10 minutes, and then at 23V 
overnight.The gel was transferred in depurination solution  for 35 minutes and washed in ddH2O 
followed up by incubation in denaturation solution for 35 minutes. 
2.3.4.2. Transfert onto a nylon membrane: 
DNA was then transferred on a nylon membrane (Hybond-N+, GE Healthcare) in 20xSSC buffer by 
means of an overnight capillarity transfer (see figure x). 
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Figure 6 This figure shows how the wicking transfer apparatus was put together. A: Three pieces of Whatman paper, 
soaked in 20x SSC, and with the ends resting in the buffer reservoir. B: Saranwrap, with a hole the size of the gel cut 
in it. This will stop evaporation from the reservoir and ensure that the only route for the buffer to get to the absorbent 
paper is through the gel and membrane. C: The gel, laid to cover precisely the hole in the Saranwrap. D: The H+ 
Hybond nylon membrane, cut to exactly the same size as the gel. E: Three more pieces of Whatman paper, cut to the 
same size as the gel, and soaked in 20x SSC. 
The membrane was then removed, washed in 100mM Tris pH8, dried in between two pieces of 
Whatman paper and DNA was crosslinked to the membrane using a UV crosslinker (. The nylon 
membrane was transferred into a hybridization oven with a prewarmed hybridization buffer, stayed  at 
55°C over night. 
2.3.4.3. Probe preparation: 
PCR was performed to amplify BSD fragments and the PCR product was purified using the Qiagen 
PCR purification product protocol and kit. DNA concentration was monitored using nanodrop. Then, 
the probe was prepared using an Amersham kit, and diluted from 150 and 100ng in 8µl of H2O 
(provided by the kit). The probe was kept 5 minutes at 100°C and directly transferred on ice for 5 
minutes. Subsequently 10µl of reaction buffer, 2µl of labelling reagent and 10µl of cross linker 
worker solution (all provided by the kit) were added. Probes were kept at 37°C during 30 minutes and 
finally stored at -20°C. 
To probe the DNA, the BSD probe was added to the hybridization buffer and left overnight in the 
oven at 55°C. The solution was removed from the tube and primary wash buffer was added for 10 
minutes at 55°C two times. The wash buffer was removed and secondary wash buffer was added for 5 
minutes at room temperature two times. 1.5mL of detection reagent (CPN stars) was  spread on the 
membrane and autoradiography was used for revelation. 
The membrane was then stripped,60mL of boiling 0.1% SDS was directly added and membrane was 
incubated  1 hour at 55°C. The membrane was rinsed for 5 to 10 minutes in Tris pH 8.0 100mM and 
dried between two pieces of Whatman paper and kept dry at room temperature. The re-probing using 
another probe was then realised as described above. 
2.4 Biochemistry methods 
2.4.1 Co-immunoprecipitation using HA tag 
To avoid degradation of the proteins, all the manipulations were done on ice. Parasites pellet was 
resuspended in 400L of ice-cold M-Per mammalian protein extraction buffer (Thermo scientific), 
Roche protease inhibitors cocktail tablets 1:25 and benzonase 1:500 (Novogen). Samples were kept 
on ice for 10 minutes, centrifuged for 15 minutes at 11000g at 4°C and supernatant was transferred 
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into a clean eppendorf. The concentration was measured by spectrometry against a BSA range. The 
concentration was adjusted for each condition to have the same concentration in all samples.  
100 g of proteins extract (PE) was kept to check the presence of the tagged proteins by western 
blot.Laemmli 2X was added the PE tubes and the samples were boiled 5 minutes, centrifuged 3 
minutes at 16000g and stored at -80°C. 
To perform the IP, 6l of beads linked to anti-Has were transferred in the column (both provided in 
the kit).  Beads were then pulse-centrifugated for 10 s at 500g at 4°C and the flow through discarded. 
PE was loaded in the column and incubated at 4°C overnight with agitation. Then, a first pulse 
centrifugation was done and the flow through (FT) was resuspended in Laemmli, boiled, centrifuged 
and stored as described above. Subsequently, 3 washes were done on the beads using 500l of TBS 
buffer and hot Laemmli 4X was added to the column. The column was transferred in an eppendorf, 
incubated at 100°C for 5 minutes and centrifuged 3 minutes at 16000g. Fifty percent were 
resuspended in Laemmli 4X to be used as a control for the IP (AfIP) and stored at -80°C. the eighty 
five other percent were used for mass spectrometry analysis after migration on a 10% 
polyacrylamide gel. 
2.4.2 Western blot 
2.4.2.1. Migration: 
10% polyacrylamide gels were used to separate proteins. Proteins samples as prepared in 2.4.1 and 
Pageruler prestained proteins (Fermentas) were loaded in the wells. Migration in the stacking gel was 
set at 80V for 20 minutes and 180 V for 1 hour in the running gel. One gel was used for Coomassie 
staining and the other for western-blot. 
2.4.2.2. Coomassie staining: 
Gels were stained in fresh Coomassie stain for 15min at room temperature with gentle agitation. 
Then gels were destained in Destain solution for 1h with gentle agitation and dried 
2.4.2.3. Gel transfer: 
Proteins were transferred to a nitrocellulose membrane using a semi-dry transfer apparatus (25V, 
200mA for 1 hour). The nitrocellulose membrane was blocked overnight at 4°C in blocking buffer and 
incubated with primary antibody or anti-HA peroxidase for 2 hours at room temperature with 
agitation. The membrane was washed (3 times for 10min) with cold PBS-T (0.1%) and incubated for 
1hour at room temperature with the secondary antibody (not required for anti-HA revelation 
because the antibody was already coupled to perxidase). The membrane was finally washed three 
times and signal developed using the chemiluminescence system (ECL, Perkin-Elmer). 
2.5 Mass spectrometry analysis 
2.5.1 Preparation of gel for mass spectrometry analysis 
After immunoprecipation (see section 2.4.3) samples were boiled 5 minutes at 100°C and centrifuged 
3 minutes at 16000 g. Then samples were loaded on a 10% polyacrylamide gel for protein separation 
(see section 2.4.1), migration was done first at 80V for 3 minutes then at 180V until first and last 
bands were separated by 2.5 to 3cm. The gel was then washed 3 times for 5 minutes with ddH2O. 50 
mL of biosafe Coomassie was added on the gel and tank with the gel and coomassie incubated for 1 
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hour. Then gel was washed again with excess of ddH2O for 30 minutes. Finally the gel was stored in 
10% ethanol and 1% acetic acid at 4°C and sent to the proteomics platform for further analysis. 
2.5.2 Mass spectrometry analysis 
Mass spectrometry analysis was performed by Romain Hamelin from the proteomics core facility at 
EPFL. In summary the gel was scan and spot corresponding to immunoreactive region were excised 
from the coomassie staining gel. The tryptic peptides were separated after in –gel digestion by 
nanoflow rpHPLC and analysed on a mass spectrometer. Data search was performed using Mascot 
2.2 in Proteome Discoverer against a database of proteins. Finally the result was given via the 
Scaffold3 protein software. 
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3. Interactome study of PfCK2β subunits and PfGSK3 
3.1 Polyacrylamide gel preparation and result before MS analysis 
3.1.1 Introduction 
For this experiment we have used proteins having a Haemaglutin tag. This tag was used to 
immunoprecipitate the proteins using agarose beads coupled with anti-HA. As a controle we have 
used 3D7A parasite lines which did not expressed proteins with a HA tag. 
In order to accumulate enough proteins for interactome studies several rounds of expansion and 
Saponin lysis were done on unsynchronised P.falciparum cultures to allow accumulation of parasites 
pellets. Before the IP we have adjusted the concentration of proteins in order to load the same 
amount in all samples. To ascertain that the IP worked, three samples were taken during the process: 
one before the IP on the protein extract (PE), one was the flow through of the IP (FT) and finally one 
sample was 15% of the eluted proteins (AfIP). These three samples were loaded on polyacrylamide 
gels for coomassie staining and western bloting. The coomassie was used to control that the same 
amount of proteins had been loaded (data not shown) for each samples. One western blot gel was 
used to control the presence of the kinase of interest using an anti-HA peroxidase antibody and the 
second one using an antibody specific for the kinase (not used in the case of PfCK2β2 because of the 
very low efficiency of the antibody). Due to the time scale of this project we have decided that if one 
control of IP work all the samples would be analysed. Mass spectrometry analyse was performed by 
Romain Hamelin who scanned the gel to confirm the presence of proteins and further processed the 
samples as described in materials amd methods part.. Finally the results was given back in a Scaffold3 
protein software. 
Since there are not many examples of such a study with P. falciparum proteins in the literature the 
quantity of proteins to be loaded was determined based on previous knowledge on mass 
spectrometry analysis with different organisms (Marc Moniatte and Romain Hamelin) and on 
parasite  (Jean Halbert and Jean-Philippe Semblat). 
 
3.1.2 Experiment 1 
For the first experiment we added Nek1 (also has an HA tag) that is a protein studied in the lab by 
Dominique Dorin-Semblat. Thus in this experiment we used five different lines: PfCK2β1HA, 
PFCK2Β2HA, PFGSK3HA, PfNEK1HA and finally 3D7. For the IP we loaded 1.718 mg of proteins in 
column with 6 ul of beads, for the control we loaded 20ug for the PE and FT per polyacrylamide gel 
and 5% of the eluted proteins after IP. Below we presented results for the control western blot 
revealed with kinase specific antibodies: 
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Figure 7: Control results for experiment 1: panel A for PfCK2β1 no bands were saw in the flow through whereas a band 
appears corresponding to the expected size for the PfCK2b1HA protein in the elution after immunoprecipitation. Panel B: 
the immunoprecipitation performed wellAfIP band) but there was still some proteins in the flow through. 
In this experiment the western blot analysis with anti-HA peroxidase antibodies was not successful, 
this was also the case for pfnek1ha proteins but this can be explained by the fact that the C-terminal 
part of the protein is normally processed which leads to the loss of the HA tag (based on discussion 
with Dominique Dorin-Semblat )  but since western blot worked with kinases specific antibodies for 
PfCK2β1 and pfgsk3 a polyacrylamide gel was prepared and sent for mass spectrometry analysis. As 
shown in the figure 2 six bands were analyzed for each sample. 
 
Figure 8 Scan of the gel experiment.1 showing cut bands for each samples of NEK1|3D7A|GSK3|CK2B2|CK2B1 
 
3.1.3 Experiment 2 
The same protocol was applied for the second experiment but this time 1.468 mg was loaded for the 
IP and we only analysed our protein of interest in this project (same proteins except pfnek1). 
III. Interactome study 
- 20 - 
Unfortunately another difference with the first experiment was the partial loss of PfCK2β2 samples 
during the process causes by technical problem with the column used for immunoprecipitation. 
 
Figure 9 Control results for experiment 2. Panel A and B: western blot analysis with kinase specific antibodies shows the 
presence of proteins in the immunoprecipitate AfIP. Panel C: shows western blot analysis with the anti-HA peroxidase 
antibody for PfGSK3HA and also the presence of the proteins in the immunoprecipitate. 
Once again the western blot with anti-HA peroxidase antibody did not work for both PfCK2b subunits 
but shows the presence of the proteins of interest in the three other samples. 
 
Figure 10 Scan of the gel experiment.2 before in-gel digestion showing the 8 bands cut and analysed. Lane B shows a 
clearly decreased intensity of coomassie staining. 
As mentioned above the quantity of proteins used in the PfCK2β2 IP was smaller compared to the 
other samples. This was confirmed by looking the coomassie staining of the lane B compared to the 
III. Interactome study 
- 21 - 
other. Nevertheless few proteins were found in this sample after mass spectrometry analysis. Finally 
note also that this time we made a longer migration in order to allow a better separation and 
analysis of the samples. 
3.1.4 Experiment 3 
For the last experiment we have used a smaller quantity of beads during immunoprecipitation (4ul 
instead of 6 ul) and the IP was done with 1.716mg of proteins per sample. In this experiment only 
one control worked. Nevertheless the sample was still sent for MS analysis. 
 
Figure 11 Western blot analysis revealed with anti-HA peroxidase antibody showing presence of PfGSK3HA in the 
immune precipitate. 
The same way as in experiment 2 we allowed the samples to migrate longer resulting in more 
separated bands which have allowed cutting 8 bands. 
 
Figure 12 Scan and bands cut for the last gel experiment 3. Biosafe coomassie staining of this gel has been staying shorter 
than with the other gel which explains the lower intensity observed. As a result, the lower coloration was not due to a 
smaller quantity of proteins loaded. 
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3.2 Scaffold 3 results 
3.2.1 Methods used to analyse the results 
The Scaffold 3 software gives for each protein found in the sample a large range of information 
including : the number of unique peptides found, how many times a given peptide appeared, the 
mascot statistic  scored for each peptide, the protein ambiguity (in case of high homology with other 
proteins) etc. In order to analyse data we have chosen three conditions under which we considered a 
given result as a potential hit: 
1. If protein only coimmunoprecipitates with our proteins of interest and not in the 3D7 control 
2. If at least 4 different peptides with a probability higher than 95% was found in the samples 
and no more than 1 peptide with a probability smaller than 95% was found in the control. 
3. Finally if more than 10 unique peptides were found in the sample and no more than 1 in the 
control (all with a probability higher than 95%) 
 
Almost all the values presented further will have a certain probability. Each probability is represented 
by colour labels and we give below the related table: 
 
3.2.2 Results for PfCK2β subunits 
First to control the efficiency of the IP we investigated the presence of our proteins of interest in the 
three experiments. Furthermore since it was shown that all pfck2 subunits interact in vitro we also 
investigated the presence of the two other subunits in the immunoprecipitates: 
Table1: Illustration of PfCK2α & PfCK2β2 co-immunoprecipitating with PfCK2β1 
EXPERIMENT PROTEIN 
NUMBER OF UNIQUE 
PEPTIDES IN CK2Β1 
IMMUNOPRECIPITATE 
NUMBER OF 
UNIQUE PEPTIDES 
IN THE CONTROL 
TOTAL NUMBER OF 
PEPTIDES IN CK2β1 
IMMUNOPRECIPITATE 
TOTAL NUMBER 
OF PEPTIDES 
CK2β1/3D7A 
%COVERAGE 
OF THE 
PROTEIN 
1 
PfCK2α 16 1 161 1 57 
PfCK2β1 9 1 31 1 59 
PfCK2β2 13 0 37 0 29 
2 
PfCK2α 15 5 44 5 21 
PfCK2β1 7 0 14 0 38 
PfCK2β2 9 0 35 0 25 
3 
PfCK2α 13 0 52 0 51 
PfCK2β1 3 0 9 0 13 
PfCK2β2 8 0 22 0 25 
 
For PfCK2β1 the three subunits were found in each experiment which confirmed the expected result 
since it has been shown that all subunits interact in vitro. In each experiment the higher number of 
peptides found belong to the PfCK2α subunit, this may be due to higher number of trypsin digestions 
sites on the protein sequence and, or to the digestion bands. Overall the coverage of proteins was 
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quite good. The maximum coverage were found for PfCK2β1 in the first experiment with a 59% 
coverage with surprisingly less unique peptides compared to the other subunit in the same 
experiment, this can be explained by the fact that PfCK2β1 is a smaller protein ( 245 amino acids) 
compared to the other subunits (PfCK2α : 335 amino acids and PfCK2β2 : 385 amino acids). The 
coverage was also dependent of the peptides size resulting from the trypsin digestion but as before 
this has not been investigate. 
Unfortunately 5 unique pfck2ba peptides were found in the control of the second experiment, but 
since the difference between the control and the immunoprecipate was quite high in terms of unique 
peptides (15/5) and of total number of peptides (44/5), we have considered PfCK2α as a hit in this 
experiment. For the same reason we have excluded the idea that those peptides were due to cross 
contamination because only 5 peptides were found compared to 161, 44 and 52 found in the 
immunoprecipitates. 
For PfCK2β2 subunits results were quite similar. The three subunits were found in all the 
immunoprecipitates with a quite similar amount: 
Table 2: Illustration of PfCK2α & PfCK2β1 co-immunoprecipitating with PfCK2β2 
EXPERIMENT PROTEIN 
NUMBER OF UNIQUE 
PEPTIDES IN CK2Β2 
IMMUNOPRECIPITATE 
NUMBER OF UNIQUE 
PEPTIDES IN THE 
CONTROL 
TOTAL NUMBER OF 
PEPTIDES IN CK2β2 
IMMUNOPRECIPITATE 
TOTAL NUMBER  
OF PEPTIDES 
CK2β1/3D7A 
%COVERAGE 
OF THE 
PROTEIN 
1 
PfCK2α 17 1 188 1 58 
PfCK2β1 11 1 24 1 25 
PfCK2β2 10 0 33 0 63 
2 
PfCK2α 17 5 59 5 21 
PfCK2β1 9 0 22 0 51 
PfCK2β2 9 0 40 0 26 
3 
PfCK2α 16 0 105 0 58 
PfCK2β1 7 0 26 0 33 
PfCK2β2 8 0 33 0 25 
 
Interestingly, although a lower amount of proteins was loaded for PfCK2β2 experiment 2, we were 
quite surprised that the higher number of PfCK2β2 peptides were found in this experiment.. 
To investigate potential functions of both subunits in the parasite we used malaria parasite metabolic 
pathway site (http://sites.huji.ac.il/malaria/). After we selected all the potential interactors for both 
subunits, we searched those proteins on the web sites. Below we presented the number of hits 
found for each process. Note that we presented the number of different proteins found in each 
process but some proteins belong to various processes, consequently there were more hits than 
proteins. Note also that in order to avoid overloading this part the list of selected proteins were 
listen in the annexe1. 
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Histogram 1: distribution of potential interactors of PfCK2β1 & PfCK2β2 respectively in blue and red, sorted by metabolic 
process - experiment 1 
 
For the first experiment, we identified 83 potential hits for PfCK2β1 and 63 of them fit in process 
analysed. For PfCK2β2 32 potential interactors out of 41 fit in process described below. Based on first 
experiment results it seems there was metabolic process involving only one subunit (cell-cell 
interaction, hemoglobin digestion), there was a lot of processes involving both subunits (post-
translationnal modification, translation, mitosis and chromosome assembly), and finally only one 
process where our proteins of interest were not involved (morphological development of blood 
forms). Those results were quite different in the second and third experiments (Histograms 2 and 3). 
In the second experiment only 42 potential interactors were found for PfCK2β1 and 37 distributed in 
the process. The difference between experience 1 and 2 was mainly due to differences between 
controls in the two experiments (see annex 2). A lot of proteins selected in the first experiment were 
found in the control of the second which explained these decreased numbers of hits. For PfCK2β2 
only 6 potential hits were found, this very low number of potential interactors was also due to the 
divergence between controls but also mainly caused by the low amount of proteins loaded for this 
experiment. Finally for the third experiment we used fewer beads, which may explain that only 12 
hits were found for PfCK2β1 (out of 13) and 21 for PfCK2β2 (out of 24). Nevertheless the same 
processes were highly represented in all the experiments (post –translationnal modification, mitosis 
and chromosome assembly and translation), there was no proteins belonging to the morphological 
development of blood form process., finally two pathways contained one of the two beta subunits. 
 Since the mass spectrometry results were given shortly before the end of the project it was not 
possible to treat all the processes in details. We decided to treat only the two most represented 
processes in terms of numbers of potential interactors. The most represented processes were post-
translational modification and mitosis and chromosome assembly with respectively 58 and 48 hits. 
Then for each process we analysed the pathway containing more potential interactors. The first 
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process treated was mitosis and chromosome assembly. Between the eleven pathways fit in this 
process, the most represented was nucleosome assembly and regulation.  
Histogram 2: distribution of potential interactors of PfCK2β1 & PfCK2β2 respectively in blue and red, sorted by metabolic 
process - experiment 2 
 
Histogram 3: distribution of potential interactors of PfCK2β1 & PfCK2β2 respectively in blue and red, sorted by metabolic 
process - experiment 3 
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Table 4: Number of proteins observed for each mitosis and chromosome separation pathways sorted by kinases and 
experimentations and total number of such proteins 
MITOSIS AND CHROMOSOME SEPARATION CK2β1.1 CK2β2.1 CK2β1.2 CK2β2.2 CK2β1.3 CK2β2.3 TOTAL 
CENTRIOLE PROTEINS  1 0 1 0 0 0 2 
CENTROSOMES PROTEINS 4 3 7 2 3 5 24 
CHROMOSOME DYNAMICS IN CELL CYCLE THAT LEADS TO 
ANAPHASE 
0 0 0 0 0 0 0 
HISTONE LYSINE METHYLATION 0 0 0 0 0 0 0 
KINETOCHORES POWER CHROMOSOME MOVEMENTS IN 
MITOSIS 
1 0 0 0 1 0 2 
NUCLEOSOME ASSEMBLY AND REGULATION 10 4 0 0 1 4 19 
PROTEINS INVOLVED IN STEPS DURING PASSAGE THROUGH 
PROPHASE 
1 1 0 0 0 0 2 
PUTATIVE ORGANIZATION OF THE KINETOCHORE  0 0 0 0 0 2 2 
REGULATION OF SPINDLE MICROTUBULE DYNAMICS 1 0 1 0 1 0 3 
STRUCTURE AND ORGANIZATION OF CENTROMERIC 
CHROMATIN 
0 0 0 0 0 2 2 
STRUCTURE OF THE MITOTIC CENTROSOME  1 0 1 0 0 0 2 
THE MITOTIC SPINDLE OF P.FALCIPARUM 0 0 0 0 0 0 0 
 
Interestingly we noticed that potential hits were not present in all the pathways. Unfortunately we 
also noticed that potential interactors were not nicely distributed in all experiments as it was the 
case for the three subunits. To assess if proteins found have a good probability to be interactors, we 
compared the three experiments simultaneously to control that the protein was not only absent in 
one control but in all controls. Table 5 and 6 give the results obtained for potential PfCK2β1 and 
PfCK2β2 interactors. 
Table 5: Number of unique potential interactors peptides involved in the nucleosome assembly and regulation pathway 
in the case of three PfCK2β1 experimentations as compared to their presence in three control immunoprecipates 
experimentations. Colours still refer to probabilities (see 3.2.1) 
NAME PLASMO DB 3D7A1 3D7A2 3D7A3  CK2β1 1 CK2β1 2  CK2β1 3 
histone H2a PFF0860c 0 1 0 3 2 1 
Smarca related protein PFF1185w 0 0 0 6 0 0 
Histone H2B PF07_0054 0 2 0 5 3 0 
nucleosome assembly protein PFI0930c 0 3 0 3 5 1 
nucleosome assembly protein 1 PFL0185c 0 9 1 3 8 2 
chromodomain helicase DNA binding protein1 PF10_0232 0 0 0 2 0 0 
high mobility group protein MAL8P1.72 0 1 1 2 1 1 
structure specific recognition protein PF14_0393 0 0 0 2 0 0 
histone H2a variant PFC0920w 1 3 1 5 4 1 
histone H2B variant  PF11_0062 1 4 0 5 5 3 
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Table 6: Number of unique potential interactors peptides involved in the nucleosome assembly and regulation pathway 
in the case of three PfCK2β2 experimentations as compared to their presence in three control immunoprecipates 
experimentations. Colours still refer to probabilities (see 3.2.1) 
NAME PLASMO DB 3D7A1 3D7A2 3D7A3  CK2β2 1 CK2β2 2  CK2β2 3 
chromodomain helicase DNA binding protein PF10_0232 0 0 0 5 0 0 
nucleosome assembly protein PFI0930c 0 3 0 2 1 0 
nucleosome assembly protein 1 PFL0185c 0 9 1 3 3 1 
smarca related protein PFF1185w 0 0 0 2 0 0 
histone H2B PF11_0062 1 4 0 5 2 4 
histoneH4 PF11_0061 2 2 0 4 0 3 
histone H3 PFF0510w 2 3 0 4 0 3 
histone H2B PF07_0054 0 2 0 3 0 2 
Interestingly Smarca-related protein and chromodomain helicase DNA binding protein were present 
one time with both beta subunits and absent in all the controls. Furthermore each appeared with at 
least 3 unique peptides which are criteria of robustness. Nevertheless reproducibility between 
experiments was highly missing to give a cleared conclusion. Structure specific recognition protein 
was also only present in one sample and not present in any control, but the reproducibility was still 
lacking and furthermore there was only 2 peptides. Many of the other potential hits appeared in two 
samples but also in one or two controls which did not allow us to give any conclusion. Furthermore 
we noticed that there was a huge difference (already mentioned) between 3D7A2 control and the 
two others. 
The second process we decided to focus on was post-translational modification. Table7 shows the 
details for the numbers of hits in each pathway for all experiments. 
 
The most represented pathways were protein kinase coding genes and calcium-calmodulin activation 
of proteins kinases. But since all the PfCK2 subunits fit in those pathways in all experiments there 
were only 2 proteins in the first one and none in the second that were not one of the subunits.. 
Based on this we decided to analyse the chaperone assisted protein folding pathway. Tables 8 and 9 
show the potential hits for PfCK2β1 and PfCK2β2. 
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Table7. Number of proteins observed for each post-translational modification pathways sorted by kinases and 
experimentations and total number of such proteins 
POST-TRANSLATIONAL MODIFICATION CK2Β1.1 CK2Β2.1 CK2β1.2 CK2β2.2 CK2β1.3 CK2β2.3 TOTAL 
14-3-3 PROTEIN 0 0 0 0 0 0 0 
ACTIVATION OF eiF5A 0 0 0 0 0 0 0 
CALCIUM-CALMODULIN ACTIVATION OF PROTEIN KINASES 3 3 3 3 3 3 18 
CHAPERONE-ASSISTED PROTEIN FOLDING  3 0 7 0 2 3 15 
COTRANSLATIONAL CLEAVAGE OFN-TERMINAL 
METHIONINERESUDUES AN N-TERMINAL ACETYLATION 
0 0 6 0 0 0 6 
GENES CODING FOR CHAPERONES AND THEIR REGULATORS 3 0 5 0 2 4 14 
GENES CODING FOR COMPONENTS OF THE PROTEASOME 
DEGRADATION MACHINERY AND THEIR TIMED 
TRANSCRIPTION 
0 1 0 0 1 0 2 
GENES CODING FOR GPI-ANCHORED MEMBRANES PROTEINS 0 0 0 0 0 0 0 
HISTONE ACETYLATION 4 0 0 0 1 4 9 
HISTONE LYSINE METHYLATION 0 0 0 0 0 0 0 
N-MYRISTOYALTION, S-ACYLATION AND PRENYLATION OF 
PROTEINS 
0 0 0 0 0 0 0 
PEPTIDASES AND PROTEASES 2 0 4 0 1 0 5 
POST-TRANSLATIONAL MODIFICATION-SUMOYLATION 0 0 0 0 0 0 0 
PROTEASOME-MEDIATED DEGRADATION OF NON-NATIVE ER 
PROTEINS 
0 0 0 0 0 0 0 
PROTEASOME-MEDIATED PROTEOLYSIS OF UBIQUINATED 
PROTEINS 
0 0 4 0 1 0 5 
PROTEIN ARGININE METHYLATION 1 0 0 0 0 2 3 
PROTEIN KINASE CODING GENES 3 4 4 3 3 3 20 
PROTEIN PHOSPHORYLATION 3 1 0 0 0 0 4 
ANAPHASE PROMOTING COMPLEX UBIQUITIN-LIGASE 0 0 0 0 0 0 0 
SCF (Skp1-Cullin-F-box) UBIQUITINE LIGASE 0 0 0 0 0 0 0 
 
Table 8: Number of unique potential interactors peptides involved in the chaperone assisted protein folding pathway in 
the case of three PfCK2β1 experimentations as compared to their presence in three control immunoprecipates 
experimentations. Colours still refer to probabilities (see 3.2.1) 
NAME PLASMO DB 3D7A1 3D7A2 3D7A3  CK2β1 1 CK2β1 2  CK2β1 3 
ATP dependent CLP protease PF14_0063 0 0 0 2 0 0 
peptidyl-prolyl-cis-transchomerase PF11_0164 0 11 2 2 11 0 
DNA binding chaperon PFL0815w 0 0 0 2 0 0 
FK506 binding protein PFL2275c 6 0 0 13 4 0 
T-complex protein 1 gamma subunit PFL1425w 9 0 0 9 2 2 
p23 co-chaperon PF14_0510 0 0 0 0 2 0 
heat shock 40KDa protein PFB0595w 0 0 0 0 3 0 
TCP1/ cpn 60 chaperonin family PFC0350c 8 1 0 5 4 0 
TCP1/ cpn 60 chaperonin family PF11_0331 18 1 0 12 4 1 
T-complex beta subunit PFC0285c 12 5 0 5 10 6 
endoplasmin homologue precursor PFL1070c 28 22 1 29 24 6 
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Table 9: Number of unique potential interactors peptides involved in the chaperone assisted protein folding pathway in 
the case of three PfCK2β2 experimentations as compared to their presence in three control immunoprecipates 
experimentations. Colours still refer to probabilities (see 3.2.1) 
NAME PLASMO DB 3D7A1 3D7A2 3D7A3  CK2b2 1 CK2b2 2  CK2b2 3 
T-complex protein beta subunit PFC0285c 12 5 0 3 0 3 
endopoasmic homologue precursor PFL1070c 28 22 1 22 0 8 
 
For this pathway most of the selected proteins during a given experiment are found in the control of 
another experiment excepted for three proteins. Nevertheless these three proteins are not found in 
more than one experiment thus no conclusion could be drawn.  
To conclude this part concerning beta subunit we presented the most ‘’ robust’’ result between the 
hits candidates which have been found to co-immunoprecipitate with PfCK2β2 in all experiments, 
with sufficient numbers of peptides to be considered as robust results and with a high recognition 
probability: 
Table 10: Number of unique Rifin Peptides observed in the case of three  PfCK2β2 experimentations as compared to their 
presence in three control immunoprecipates experimentations. Colours still refer to probabilities (see 3.2.1) 
NAME PLASMO DB 3D7A1 3D7A2 3D7A3  CK2b2 1 CK2b2 2  CK2b2 3 
Rifin PFD1020c 0 0 0 4 4 3 
  
3.2.3 Results for PfGSK3 
We have first analysed the presence of the proteins in all experiments to control the efficiency of the 
IP: 
Table 10: Number of unique PfGSK3 peptides observed in all immunoprecipitates and in their control 
EXPERIMENT PROTEIN 
NUMBER OF UNIQUE 
PEPTIDES IN GSK3 
IMMUNOPRECIPITATE 
NUMBER OF UNIQUE 
PEPTIDES IN THE 
CONTROL 
TOTAL NUMBER OF 
PEPTIDES IN GSK3 
IMMUNOPRECIPITATE 
TOTAL NUMBER 
OF PEPTIDES IN 
THE CONTROL 
%COVERAGE OF 
THE PROTEIN 
1 PfGSK3 25 2 153 3 51 
2 PfGSK3 17 1 73 2 39 
3 PfGSK3 16 0 79 0 37 
 
PfGSK3 was found in all the samples with numerous unique peptides and a good coverage of the 
protein. Furthermore proteins peptides were found only at a low level in the control. In the same 
way as for the analysis of the interactome of the other proteins of interest we have selected 
potential interactors  for each experiment and report them on a histogram to have an overview. 
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Histogram 4: Distribution of potential interactors of PfGSK3 in the three aforementioned experimentations sorted by 
metabolic process 
 
 There was a huge variation of proteins in the PfGSK3 samples, but based on these preliminary 
results, it seems that PfGSK3 was not involved in several processes (invasion and motility, 
morphological development of blood forms, cell-cell interactions and carbohydrates). There were 
only two processes where potentials proteins were found in every experiment. This was probably 
due to the 3D7A2 control as for the PfCK2β subunits and   to the lower amount of proteins loaded in 
experiment 3. The experiment 1 analysis resulted in the selection of 28 potentials hits (4 did not 
belong to any process), 20 in the experiment two and only 5 in the last experiment. 
 
 
0 1 2 3 4 5 6 7 8
lipids
nucleotides
amino acids
carbohydrates
cofactors and other substrates
redox metabolism
hemoglobin digestion
organellar functions
protein traffic
replication
mitosis an chromosome assembly
transcription
translation
post-translationnal modification
transport
cell-cell interactions
morphological development of blood forms
invasion and motility
GSK3 EXPERIMENTS
GSK3.3
GSK3.2
GSK3.1
IV. Reverse genetics studies 
- 31 - 
 
4. Reverse genetics studies of PfCK2β subunits 
 
For this experiment we have used 4 parasites lines. KOCK2β1 + complement 2 and KOCK2β2 + 
complement 1  
The aim here was to assess if both PfCK2β subunits gene could be disrupted in the presence of a 
complementation plasmid (providing the wilt type gene). Integration was first monitored using PCR 
then the populations were analysed by Southern blot. 
4.1 PfCK2β1 
For the PCR, DNA was extracted from KOCK2β1 + complement 2 cultures. Then PCR amplification has 
been done using oligonucleotides as detailed in table 1. 
Table1: oligonigonucleotides used for DNA amplification and detection of integration. Numbers between brackets 
correspond to numbers in figure 2 showing their localisation on the plasmids and the gene.   
Band to be amplified Forward oligonucleotide Reverse oligonucleotide Expected size of 
amplified band (bp) 
Wild type CK2b15primeF (1) CK2b13primeRev (2) 934 
5’ integration CK2b15primeF (1) pCAMBSDRev (4) 598 
Plasmid pCAMBSDFor (3) pCAMBSDRev (4) 604 
 
 
 
Figure 13 Experiment was done on two different cultures. Lane 1: wild type (primer 1 & 2; size 934bp), lane 2: 5’ 
integration (primer 1 & 4; size 598bp), lane 3: episome (primer 3 & 4; size 604bp). 
After several weeks of culture, there was still no sign of 5’ integration. This may be due either to a 
very low level of integration or to premiers’ bias. To determine the populations present in the culture 
we performed a Southern blot. After phenol extraction, DNA digestion was done using enzyme Cla1 
and EcoR1. Digestion was performed on the two populations (KOCK2β1 and KOCK2β1 + comp 2). We 
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used first a BSD probe hybridizing to the episome bands and to the recombinated bands. The 
membrane was then stripped and probed using a PfCK2β1 probe which hybridizes to the wild type 
locus band. 
Figure 2 Sites for restriction enzyme digestion and expected size of fragments 
 
Figure 3 Diagram showing the sites for the restriction enzymes and the oligonucleotides primers used. 
 
 
Figure 4 Knockout studies: lane 1: KOCK2β1 + comp2, lane 2: KOCK2β1, lane 3 : 3D7A. A band at the expected size for the 
integration appeared only in KO lines. 
Southern blot analysis revealed a band related to the integration of the koplasmind only in the 
KOCK2β1 line. This result was not the expected one since Southern blot analysis on the other double 
transfected line has shown that the integration only appeared in the complemented line. As a result, 
in order to determine if this band corresponded really to integration a PCR was to be done using the 
digested DNA to amplify this band. If the PCR worked it would have meant that the gene was not 
essential. Otherwise this band could be due to a mistake when the gel was loaded or due to an 
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artefact (unspecific recombination). Finally the decreased intensity of the wild type band in lane 1 
was not necessarily caused by the diminution of the WT population, since the amount of digested 
DNA loaded on this lane was lower than in lane 2 and 3. 
  
4.2 PfCK2β2 
An experiment was performed the same way for the second subunit. The primers used for PCR 
amplification is shown in the table 2 below and the PCR results are presented in figure 4. 
Table2: oligonigonucleotides used for DNA amplification and detection of integration. Numbers between brackets 
correspond to numbers in figure 5 showing the localisation on the plasmids and the gene.   
Band to be amplified Forwards oligonucleotide Reverse oligonucleotide Expected size of 
amplified band (kb) 
Wild type CK2b25primeF (1) CK2b2RSpe (2) 1.3 
5’ integration CK2b25primeF (1) pCAMBSDRev (4) 1.1 
Plasmid pCAMBSDFor (3) pCAMBSDRev (4) 1.1 
 
 
Figure 14: Experiment was done on two different cultures. Lane 1: wild type (primers 1 & 2; size 1.3kb), lane 2: 5’ 
integration (primers 1 & 4; size 1.1kb), lane 3: episome (primers 3 & 4; size 1.1kb). 
In this line the integration appeared on the PCR on both lane 2 (see figure 4). We further did a 
Southern blot to confirm the presence of the integration in our population. DNA was digested with 
Cla1 and Nco1. The sizes which were expected are presented in figure 5.  
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Figure 15: Diagram showing the sites for the restriction enzymes and the oligonucleotides primers used. 
 
 
Figure 16: Southern blot result with BSD and PfCK2β2 probe. lane 1: KOCK2β2 + comp1, lane 2: KOCK2β2, lane 3 : 3D7A. A 
band corresponding to the expected size for integration appeared only in KO lines. 
 
According to the PCR results, we expected to observe integration bands for this line since we saw a 
PCR 5’integration. But we did not see any bands at the integration size. Furthermore the undisrupted 
gene was present in the two lines (complemented or not) with the same intensities and the plasmid 
was still equivalently present in both lines. Thus for this line the cultures had to be followed up 
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5. Discussion 
 
 
In this project we have used mass spectrometry analysis to study the interactome of three different 
proteins: PfCK2β1, PfCK2β2 and PfGSK3. We have shown that our proteins of interest can be 
efficiently immunoprecipitated using their HA tag. Moreover, in the case of PfCK2β subunits we have 
obtained the co immunoprecipitation of the three subunits with PfCK2β1 and PfCK2β2. It has already 
been shown in the past that the three subunits interact in vitro, thus our results add nothing new. 
However, this approach has to our knowledge never been used on Plasmodium falciparum in the 
past. We would therefore assume based on the preliminary obtained results that this approach can 
be used to study interactions of P.falciparum proteins as it has given the same results as the usual 
methods. 
 Our results are preliminary and it is not possible to give an absolute conclusion. However 
bioinformatics studies have determined that PfCK2β subunits possess a putative signal sequence for 
the nucleus. Interestingly we found proteins exerting their effect into the nucleus that 
coimmunoprecipitate only with our proteins of interest (PfCK2β1 and PfCK2β2). On the other side it 
was also proposed that PfCK2β2 could be exported since these proteins have a putative signal for 
export. And in our results we found a protein (rifin) which is known to be exported and which has 
been found in all the PfCK2β2 immunoprecipates. Once again we mention that it is impossible based 
only on three experimentations to give any definitive conclusion. We showed that this method can 
be used to identify potential interactors in P.falciparum. As mentioned in the project, there was a 
huge variability between potentials hits from one experiment to another. Furthermore there were 
many differences between our controls. To limit this variability we need to improve the stringency 
used. This can be done by increasing the number of washes after the immunoprecipitation. Another 
solution is to change the method used to elude the proteins after the IP. In this project we used 
Laemmli who elute the proteins bound to the beads without any specificity. To further remove those 
unspecific proteins we could use an HA-peptide which is a competitor to the HA epitope, thus 
proteins eluted would be only the proteins that are bound specifically by the anti HA epitope. Finally 
in this project the samples were allowed to bind to the beads over night, which may be too long for 
all the transient interactions, consequently decreasing this incubation time could lead to an increase 
in the number of hits. 
Another important point is that this method can only give potentials interactors, thus in order to 
select good hits we need to process as many experimentations as possible in order to control that 
this protein is effectively a potential interactor. Once a protein is selected the result need to be 
verified by other methods such as fluorescence resonance electron transfer to assess the existence 
of the interaction. 
Finally concerning the reverse genetics studies, we have not yet determined whether the two genes 
could be disrupted in the presence of a complementation plasmid. Further, it appears that the 
recombination between the two plasmids and/or between the plasmid(s) and the locus would need 
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to be analysed. Another possibility might be to apply a complementation plasmid with a synthetic 
gene while using different codons to avoid this recombination. Based on our results for PfCK2β1 we 
would have to determine if there has been a recombination between the KO plasmid and the wild 
type gene in the single knock out plasmid transfected line. In the event that this is not the case, 
cultures would have to be continuously carried out and continued analysis be done using Southern 
blot as for PfCK2β2. 
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7. Summary 
 
Malaria is the most devastating parasitic infection killing each year between 1 and 3 million 
of people. Furthermore this decease has a huge socio-economic impact in affected countries. 
The emergence of resistance against currently used drug makes the development of a new 
treatment an urgent task. Considering the success of kinase inhibitors in treatment of various 
cancers and considering the divergence between the parasites and human kinome, proteins 
kinases have become an attractive potential target. In this project we have used mass 
spectrometry analysis to study the Interactome of three P.flaciparum kinases: PfCK2β1; 
PfCK2β2 and PfGSK3. The genetically modified lines that we have used possess 
haemaglutinin tag. We have used this haemaglutinin tag to immunoprecipitate our proteins 
and their potentials interactors. Samples were then separated on acrylamide gel and analysed 
at the proteomics core facility at EPFL. Finally we have analysed the potential interactors and 
study the pathway in which they are involved. Using these methods we have found that the 
three PfCK2 subunits were immunoprecipitate together. These were already deemed known 
results since it has already been shown that these subunits interact together. But since there is, 
to the best of our knowledge, no example of this kind of study in P.falciparum, this project 
tends to demonstrate that mass spectrometry can be used to study Interactome of the parasites 
proteins. For our three proteins of interest we have identified some potential interactors but 
our results are too preliminary to conclude that those proteins are real interactors. A better 
understanding of the parasite life cycle and its metabolic pathway is critical in the 
development of a treatment against Malaria. 
